186 related articles for article (PubMed ID: 37464069)
1. SETBP1 is dispensable for normal and malignant hematopoiesis.
Tanaka A; Nishimura K; Saika W; Kon A; Koike Y; Tatsumi H; Takeda J; Nomura M; Zang W; Nakayama M; Matsuda M; Yamazaki H; Fukumoto M; Ito H; Hayashi Y; Kitamura T; Kawamoto H; Takaori-Kondo A; Koseki H; Ogawa S; Inoue D
Leukemia; 2023 Sep; 37(9):1802-1811. PubMed ID: 37464069
[TBL] [Abstract][Full Text] [Related]
2. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
Inoue D; Kitaura J; Matsui H; Hou HA; Chou WC; Nagamachi A; Kawabata KC; Togami K; Nagase R; Horikawa S; Saika M; Micol JB; Hayashi Y; Harada Y; Harada H; Inaba T; Tien HF; Abdel-Wahab O; Kitamura T
Leukemia; 2015 Apr; 29(4):847-57. PubMed ID: 25306901
[TBL] [Abstract][Full Text] [Related]
3. SETBP1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
Yao XY; Zhou JD; Yang J; Zhang W; Ma JC; Wen XM; Yao DM; Xu ZJ; Wu DH; He PF; Qian J; Lin J
Pathol Res Pract; 2018 May; 214(5):706-712. PubMed ID: 29549983
[TBL] [Abstract][Full Text] [Related]
4. Myb expression is critical for myeloid leukemia development induced by Setbp1 activation.
Nguyen N; Vishwakarma BA; Oakley K; Han Y; Przychodzen B; Maciejewski JP; Du Y
Oncotarget; 2016 Dec; 7(52):86300-86312. PubMed ID: 27863435
[TBL] [Abstract][Full Text] [Related]
5. Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemia.
Choi HW; Kim HR; Baek HJ; Kook H; Cho D; Shin JH; Suh SP; Ryang DW; Shin MG
Ann Lab Med; 2015 Jan; 35(1):118-22. PubMed ID: 25553291
[TBL] [Abstract][Full Text] [Related]
6. Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies.
Winkelmann N; Schäfer V; Rinke J; Kaiser A; Ernst P; Scholl S; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2511-2519. PubMed ID: 28913558
[TBL] [Abstract][Full Text] [Related]
7. ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation.
Saika M; Inoue D; Nagase R; Sato N; Tsuchiya A; Yabushita T; Kitamura T; Goyama S
Sci Rep; 2018 Oct; 8(1):15873. PubMed ID: 30367089
[TBL] [Abstract][Full Text] [Related]
8. Somatic SETBP1 mutations in myeloid neoplasms.
Makishima H
Int J Hematol; 2017 Jun; 105(6):732-742. PubMed ID: 28447248
[TBL] [Abstract][Full Text] [Related]
9. Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10.
Oakley K; Han Y; Vishwakarma BA; Chu S; Bhatia R; Gudmundsson KO; Keller J; Chen X; Vasko V; Jenkins NA; Copeland NG; Du Y
Blood; 2012 Jun; 119(25):6099-108. PubMed ID: 22566606
[TBL] [Abstract][Full Text] [Related]
10. Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development.
Vishwakarma BA; Nguyen N; Makishima H; Hosono N; Gudmundsson KO; Negi V; Oakley K; Han Y; Przychodzen B; Maciejewski JP; Du Y
Leukemia; 2016 Jan; 30(1):200-8. PubMed ID: 26205084
[TBL] [Abstract][Full Text] [Related]
11. Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies.
Acuna-Hidalgo R; Deriziotis P; Steehouwer M; Gilissen C; Graham SA; van Dam S; Hoover-Fong J; Telegrafi AB; Destree A; Smigiel R; Lambie LA; Kayserili H; Altunoglu U; Lapi E; Uzielli ML; Aracena M; Nur BG; Mihci E; Moreira LM; Borges Ferreira V; Horovitz DD; da Rocha KM; Jezela-Stanek A; Brooks AS; Reutter H; Cohen JS; Fatemi A; Smitka M; Grebe TA; Di Donato N; Deshpande C; Vandersteen A; Marques Lourenço C; Dufke A; Rossier E; Andre G; Baumer A; Spencer C; McGaughran J; Franke L; Veltman JA; De Vries BB; Schinzel A; Fisher SE; Hoischen A; van Bon BW
PLoS Genet; 2017 Mar; 13(3):e1006683. PubMed ID: 28346496
[TBL] [Abstract][Full Text] [Related]
12. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia.
Cristóbal I; Blanco FJ; Garcia-Orti L; Marcotegui N; Vicente C; Rifon J; Novo FJ; Bandres E; Calasanz MJ; Bernabeu C; Odero MD
Blood; 2010 Jan; 115(3):615-25. PubMed ID: 19965692
[TBL] [Abstract][Full Text] [Related]
13. Somatic SETBP1 mutations in myeloid malignancies.
Makishima H; Yoshida K; Nguyen N; Przychodzen B; Sanada M; Okuno Y; Ng KP; Gudmundsson KO; Vishwakarma BA; Jerez A; Gomez-Segui I; Takahashi M; Shiraishi Y; Nagata Y; Guinta K; Mori H; Sekeres MA; Chiba K; Tanaka H; Muramatsu H; Sakaguchi H; Paquette RL; McDevitt MA; Kojima S; Saunthararajah Y; Miyano S; Shih LY; Du Y; Ogawa S; Maciejewski JP
Nat Genet; 2013 Aug; 45(8):942-6. PubMed ID: 23832012
[TBL] [Abstract][Full Text] [Related]
14. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.
Sakurai M; Kunimoto H; Watanabe N; Fukuchi Y; Yuasa S; Yamazaki S; Nishimura T; Sadahira K; Fukuda K; Okano H; Nakauchi H; Morita Y; Matsumura I; Kudo K; Ito E; Ebihara Y; Tsuji K; Harada Y; Harada H; Okamoto S; Nakajima H
Leukemia; 2014 Dec; 28(12):2344-54. PubMed ID: 24732596
[TBL] [Abstract][Full Text] [Related]
15. Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
Carratt SA; Braun TP; Coblentz C; Schonrock Z; Callahan R; Curtiss BM; Maloney L; Foley AC; Maxson JE
Leukemia; 2021 Dec; 35(12):3594-3599. PubMed ID: 34002029
[TBL] [Abstract][Full Text] [Related]
16. The impact of the chromatin binding DEK protein in hematopoiesis and acute myeloid leukemia.
Wilcher KE; Page ERH; Privette Vinnedge LM
Exp Hematol; 2023 Jul; 123():18-27. PubMed ID: 37172756
[TBL] [Abstract][Full Text] [Related]
17. SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub.
Piazza R; Magistroni V; Redaelli S; Mauri M; Massimino L; Sessa A; Peronaci M; Lalowski M; Soliymani R; Mezzatesta C; Pirola A; Banfi F; Rubio A; Rea D; Stagno F; Usala E; Martino B; Campiotti L; Merli M; Passamonti F; Onida F; Morotti A; Pavesi F; Bregni M; Broccoli V; Baumann M; Gambacorti-Passerini C
Nat Commun; 2018 Jun; 9(1):2192. PubMed ID: 29875417
[TBL] [Abstract][Full Text] [Related]
18. Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells.
Zhang Y; Yan X; Sashida G; Zhao X; Rao Y; Goyama S; Whitman SP; Zorko N; Bernot K; Conway RM; Witte D; Wang QF; Tenen DG; Xiao Z; Marcucci G; Mulloy JC; Grimes HL; Caligiuri MA; Huang G
Blood; 2012 Aug; 120(5):1118-29. PubMed ID: 22740449
[TBL] [Abstract][Full Text] [Related]
19. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
[TBL] [Abstract][Full Text] [Related]
20. Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms.
Carratt SA; Kong GL; Curtiss BM; Schonrock Z; Maloney L; Maniaci BN; Blaylock HZ; Baris A; Druker BJ; Braun TP; Maxson JE
Blood; 2022 Aug; 140(6):644-658. PubMed ID: 35482940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]